161 related articles for article (PubMed ID: 32445931)
1. Treatment Variation in Older Adults With Differentiated Thyroid Cancer.
Sutton W; Canner JK; Segev DL; Zeiger MA; Mathur A
J Surg Res; 2020 Oct; 254():154-164. PubMed ID: 32445931
[TBL] [Abstract][Full Text] [Related]
2. Low-Risk Thyroid Cancer in Elderly: Total Thyroidectomy/RAI Predominates but Lacks Survival Advantage.
Zambeli-Ljepović A; Wang F; Dinan MA; Hyslop T; Roman SA; Sosa JA; Scheri RP
J Surg Res; 2019 Nov; 243():189-197. PubMed ID: 31185435
[TBL] [Abstract][Full Text] [Related]
3. Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated thyroid carcinoma: a population-based study.
Zhang H; Cai Y; Zheng L; Zhang Z; Jiang N
Hell J Nucl Med; 2017; 20(1):3-10. PubMed ID: 28315902
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns of aging Americans with differentiated thyroid cancer.
Park HS; Roman SA; Sosa JA
Cancer; 2010 Jan; 116(1):20-30. PubMed ID: 19908255
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
Yang Z; Flores J; Katz S; Nathan CA; Mehta V
Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
[TBL] [Abstract][Full Text] [Related]
6. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
7. Relapse-free survival after adjuvant radioactive iodine therapy in patients with differentiated thyroid carcinoma with a microscopically positive tumor margin.
Watanabe K; Igarashi T; Uchiyama M; Ojiri H
Ann Nucl Med; 2020 Dec; 34(12):920-925. PubMed ID: 32940889
[TBL] [Abstract][Full Text] [Related]
8. Have 2006 ATA practice guidelines affected the treatment of differentiated thyroid cancer in the United States?
Goffredo P; Roman SA; Sosa JA
Thyroid; 2014 Mar; 24(3):463-71. PubMed ID: 23978295
[TBL] [Abstract][Full Text] [Related]
9. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
10. Recurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomes.
Mihailovic J; Nikoletic K; Srbovan D
J Nucl Med; 2014 May; 55(5):710-7. PubMed ID: 24722527
[TBL] [Abstract][Full Text] [Related]
11. DEATH RELATED TO PULMONARY METASTASIS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER.
Leite AK; Kulcsar MA; de Godoi Cavalheiro B; de Mello ES; Alves VA; Cernea CR; Matos LL
Endocr Pract; 2017 Jan; 23(1):72-78. PubMed ID: 27749128
[TBL] [Abstract][Full Text] [Related]
12. Association between age and disease specific mortality in medullary thyroid cancer.
Sahli ZT; Canner JK; Zeiger MA; Mathur A
Am J Surg; 2021 Feb; 221(2):478-484. PubMed ID: 33010878
[TBL] [Abstract][Full Text] [Related]
13. Radioactive iodine in differentiated thyroid cancer: a national database perspective.
Orosco RK; Hussain T; Noel JE; Chang DC; Dosiou C; Mittra E; Divi V; Orloff LA
Endocr Relat Cancer; 2019 Oct; 26(10):795-802. PubMed ID: 31443087
[TBL] [Abstract][Full Text] [Related]
14. Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer.
Pajamäki N; Metso S; Hakala T; Ebeling T; Huhtala H; Ryödi E; Sand J; Jukkola-Vuorinen A; Kellokumpu-Lehtinen PL; Jaatinen P
Clin Endocrinol (Oxf); 2018 Feb; 88(2):303-310. PubMed ID: 29154445
[TBL] [Abstract][Full Text] [Related]
15. Surgery and Radioactive Iodine Therapeutic Strategy for Patients Greater Than 60 Years of Age with Differentiated Thyroid Cancer.
Tang T; Zhi J; Zhang W; Hu L; Ruan X; Chen X; Wang Z; Zheng X; Gao M
J Healthc Eng; 2022; 2022():4348396. PubMed ID: 35178227
[TBL] [Abstract][Full Text] [Related]
16. Racial Disparities in Differentiated Thyroid Cancer: Have We Bridged the Gap?
Shah SA; Adam MA; Thomas SM; Scheri RP; Stang MT; Sosa JA; Roman SA
Thyroid; 2017 Jun; 27(6):762-772. PubMed ID: 28294040
[TBL] [Abstract][Full Text] [Related]
17. Differentiated thyroid cancer presenting with distant metastases: a population analysis over two decades.
Goffredo P; Sosa JA; Roman SA
World J Surg; 2013 Jul; 37(7):1599-605. PubMed ID: 23525600
[TBL] [Abstract][Full Text] [Related]
18. Use of imaging tests after primary treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating death and recurrence.
Banerjee M; Wiebel JL; Guo C; Gay B; Haymart MR
BMJ; 2016 Jul; 354():i3839. PubMed ID: 27443325
[TBL] [Abstract][Full Text] [Related]
19. Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer.
Sun Y; Gong J; Guo B; Shang J; Cheng Y; Xu H
Oral Oncol; 2018 Dec; 87():152-157. PubMed ID: 30527231
[TBL] [Abstract][Full Text] [Related]
20. A comparative analysis of treatment efficacy in intermediate-risk thyroid cancer.
Abiri A; Nguyen T; Goshtasbi K; Torabi SJ; Kuan EC; Armstrong WB; Tjoa T; Haidar YM
Eur Arch Otorhinolaryngol; 2023 May; 280(5):2525-2533. PubMed ID: 36651960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
